The FDA expanded approval of talazoparib plus enzalutamide to HRR-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer following a significant radiographic PFS benefit in TALAPRO-3.
|Podcasts|April 15, 2022
Pharmacist Moms: Coffee With Suzy - Episode 12
On this week's episode, Suzy welcomes 2021 Women Pharmacist of the Year winners to celebrate their work and discuss key trends in pharmacy.
Advertisement
On this week's episode, Suzy welcomes 2021 Women Pharmacist of the Year winners Nicole K Bookstaver, PharmD, BCACP; Seena L. Haines, PharmD, BCACP, NBS-HWC, CHWC, FAPhA, FCCP, FASHP, FNAP; Bled Nguessan, PharmD; and Dixie Leikach, RPh, MBA, FACA, to celebrate these honorable women and discuss key trends in pharmacy.
Advertisement
Related to this article
Pharmacists can help care for patients receiving breast cancer endocrine therapy by identifying fracture risk early and supporting appropriate bone-directed treatment throughout survivorship.
Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.
A current pharmacy resident provides insights on how pharmacy students can manage the transition from student to resident.
Pharmacy performance measures should recognize clinical interventions, patient counseling, prescriber collaboration, and outcomes—not prescription volume alone.
CMS’s GLP-1 Bridge demo bypasses Part D to cover select obesity drugs, with a $50 monthly copay, PA workflow, and strict eligibility through 2027.
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Beyond Prescription Volume: Measuring the Pharmacist’s Value
2
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
3
FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer
4
GLP-1 RAs, Finerenone, and CKD: Key Data From Kidney Week 2026
5